After returning from the Eastern Analytical Symposium (EAS), where PerkinElmer (PKI) introduced a number of new products, the companys infrared (IR) business manager Sharon Williams discussed her views on IR and where it is going in pharmaceutical applications of process analytical technology (PAT), and talked about some of her companys new technologies.P.M.:What was the highlight of this years EAS?S.W.: The key message I took from the Eastern Analytical Symposium is the fact that the drug industrys adoption of PAT is starting to accelerate, particularly its demand for NIR and chemical imaging technologies. This adoption has been talked about for several years now, but we are finally starting to see it happen. NIR is becoming particularly important for raw materials testing, as the industry is learning that raw material quality problems all too often translate, down the line, into batch failures.P.M.:What new technologies did PerkinElmer introduce at the Symposium?S.W.: We introduced two new FT-IR and FT-NIR spectrometers, the Spectrum 100 and 100N, which include a number of features, including:
- an improved Universal Attenuated Total Reflectance (UATR) accessory, designed to help simplify measurement of solid samples and to minimize variations in measurements, between different users and different samples;
- a new fiber optic NIR probe with a user interface; and
- enhanced versions of Spectrum and AssureID software packages.